TOP > 外国特許検索 > IMMUNOMODULATOR

IMMUNOMODULATOR

外国特許コード F180009374
整理番号 (S2016-0969-N0)
掲載日 2018年4月19日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP029518
国際公開番号 WO 2018034318
国際出願日 平成29年8月17日(2017.8.17)
国際公開日 平成30年2月22日(2018.2.22)
優先権データ
  • 特願2016-160573 (2016.8.18) JP
発明の名称 (英語) IMMUNOMODULATOR
発明の概要(英語) The present invention provides a pharmaceutical composition used for the treatment or prevention of allergic diseases. More specifically, the present invention provides a pharmaceutical composition for the treatment or prevention of allergic diseases, that includes a substance that induces selective IgA class switching of B cells. A PKC activator can be used as the substance that induces selective IgA class switching of B cells. The composition including the substance that induces selective IgA class switching of B cells can be useful as a mucosal adjuvant.
従来技術、競合技術の概要(英語) BACKGROUND ART
Is allergic diseases such as asthma and hay fever, in many developed countries are older people. Allergy is, harmless antigen of the deleterious consequences of excessive immune responses to allergens is considered. IgE antibodies for a central mediator of allergic response, many of the target inhibition of IgE response for treating allergies However, there remains a fundamental for the allergic disease therapy has not been established, such as a steroid or antihistamine drug therapies are present in the treatment of all (non-patent document 1).
Allergic diseases caused by imbalance of the immune system from the idea, such as oral immune desensitization therapy and immunotherapy is attempted, is still established treatment regimen is not. Allergies for example in order to avoid exposure to food allergy removed is regarded effective diet, unknowingly take a severe allergy symptoms in a small amount of the case may occur, that is waiting for the development of the fundamental.
IgE antibodies to house dust or pollen allergy I in, such as food and enter the body of the antigen, IgE antibodies specific to them are produced. Cause is unknown, it is possible to balance the reaction Th2 is biased to enhance the production of IgE antibodies is called. IgE antibodies specific for the allergen of the structures of the basophil high affinity IgE on mast cells and binds to the receptor. Further in this state and enter the body when the allergen, allergen IgE on the cell surface in the cross-linking chemical from mast cells or basophils the transfer material may be discharged, a so-called allergic symptoms occurs. Target IgE and humanized monoclonal antibody is omalizumab, in patients with asthma have been used (Non-Patent Document 2). At the present time, to suppress the immune response of each stage of the treatment of drug administered as a general, the therapeutic agent is not sufficient.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY
  • 発明者(英語)
  • SHINKURA, Reiko
  • YAMAMOTO, Kota
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close